Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
atypical antipsychotics
Pharma
Intra-Cellular's unstoppable Caplyta nails another trial
The atypical antipsychotic medication Caplyta has been on a roll, with yet another positive late-stage trial now in the bag.
Angus Liu
Nov 5, 2024 10:15am
Intra-Cellular moves closer to Caplyta depression expansion
Apr 16, 2024 2:27pm
Rovi wins FDA nod to make Moderna's COVID shot at Spanish plant
Feb 28, 2024 11:22am
Teva taps Royalty to bankroll long-acting schizophrenia drug
Nov 13, 2023 11:40am
Takeda, AstraZeneca, Astellas and more—Fierce Pharma Asia
May 19, 2023 9:25am
Intra-Cellular's Caplyta posts sweeping win in depression trial
Mar 29, 2023 11:30am
